Science AI Journal
Biochemistry, Genetics and Molecular Biology · Research topic

Open research questions in Curcumin's Biomedical Applications

25 unresolved questions extracted from the limitations and future-work sections of 218 Curcumin's Biomedical Applications papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • A BSTRACT Traditional Chinese medicine (TCM) provides a holistic therapeutic framework with over 2000 years of clinical use; however, its molecular mechanisms remain incompletely defined.

    Convergent molecular nodes of curcumin and tanshinone IIA: A narrative review of their multidisease therapeutic scope and clinical challenges · 2026 · DOI

  • The lymphatic transport data provide qualitative evidence supporting lymphatic access of CUR-PRO, although the quantitative contribution of this pathway to the overall exposure increase remains to be established.

    Enhancing Oral Bioavailability of Poorly Water-Soluble Natural Products via Lipid–Drug Conjugates · 2026 · DOI

  • Future studies should investigate the mechanisms underlying CUR-NLC-mediated protection, including immune modulation, oxidative stress responses, bacterial tissue burden, nanoparticle biodistribution, environmental fate, and economic feasibility under commercial aquaculture conditions. However, the study was limited by the absence of long-term storage stability testing, tissue residue evaluation, histopathology, antioxidant and immune biomarker analyses, gut microbiota profiling, and farm-scale validation.

    Dietary curcumin encapsulated in nanostructured lipid carriers improves growth performance, feed utilization efficiency, and resistance to Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus) · 2026 · DOI

  • This article systematically reviews relevant domestic and international literature to summarize the research progress on the effects and mechanisms of curcumin against breast cancer, aiming to provide a reference for further research on curcumin and the development of novel anti-breast cancer drugs.

    Research Progress on the Effects and Mechanisms of Curcumin Against Breast Cancer · 2026 · DOI

  • These findings highlight the therapeutic promise of the combination treatment of DOX and CUR and warrant further research, optimization, and clinical evaluation as a novel approach to improve breast cancer treatment outcomes. Breast cancer remains a complex and life-threatening disease, with current therapies often limited by adverse effects.

    Anticancer combination effects of Doxorubicin and Curcumin on human breast cancer cell lines MDA-MB-231 and MCF-7 · 2026 · DOI

  • Despite their promise, the use of phytochemicals recovered from food and agricultural waste streams in cancer therapy faces several important limitations. The chemical com- position of waste-derived matrices is highly heterogeneous and influenced by plant species, cultivar, growing conditions, post-harvest handling, and processing methods, leading to batch-to-batch variability in phytochemical profiles, purity, and bioactivity. This variability complicates standardization, dose definition, and regulatory approval, and raises concerns about reproducibility and long-term safety (Garcia-Oliveira et al. 2021; Zhang et al. 2025). Moreover, waste streams can contain pesticide residues, heavy metals, mycotoxins, plasticizers, and process contaminants that may co-extract with the targeted bioactives, necessitating rigorous purification, quality control, and toxicological assessment (O’Connor et al. 2022; Nguyen et al. 2020). Many of these phytochemicals remain poorly characterized in terms of pharmacokinetics, bioavailability, metabolism, and interaction with conventional chemotherapeutics or patient comorbidities, creat- ing uncertainty about optimal dosing regimens and the risk of off-target effects (McCle- ments and Öztürk 2022a). In addition, large-scale, cost-effective, and environmentally sustainable extraction and fractionation processes are still under development, and the energy, solvent use, and infrastructure required for industrial valorization could par- tially offset the intended circular bioeconomy and sustainability gains. Collectively, Sharaf et al. Cancer Nanotechnology (2026) 17:24 Page 20 of 26 Fig. 3 Challenges in harnessing nano-enabled strategies to transform food waste-derived phytochemicals into standardized, bioavailable therapeutic agents these issues highlight the need for harmonized extraction protocols, validated analytical fingerprints, and comprehensive preclinical and clinical evaluation frameworks before waste-derived phytochemicals can be reliably integrated into evidence-based oncologic care (Zhang et al. 2025; McClements and Öztürk 2022b). On the nanomedicine side, nanoencapsulation of waste-derived phytochemicals introduces another layer of complexity and limitation. The design and fabrication of nanocarriers with tightly controlled size, surface charge, morphology, and ligand func- tionalization are technically demanding, and small deviations can markedly alter bio- distribution, tumor accumulation, cellular uptake, and immune recognition (Đorđević et al. 2022). In parallel, the vast majority of phytochemical-loaded nanocarriers remain confined to in vitro and small animal models with limited pharmacokinetic, biodistri- bution, and toxicological data in higher species and very few formulations progressing to early-phase clinical trials, which constrains evidence-based dose selection and risk assessment (Parvin et al. 2025). Many nanomaterials exhibit incomplete biodegradation, potential long-term tissue retention, and poorly understood chronic toxicity, especially when repeatedly administered or combined with other systemic therapies (Umapathi et al. 2022). Scale-up from laboratory formulations to reproducible, good manufactur- ing practice (GMP)-compliant industrial production is challenging due to issues such as batch variability, instability during storage, premature drug leakage, and the high cost of raw materials and manufacturing (Agrahari and Hiremath 2017). In vivo, the protein corona, opsonization, and clearance by the mononuclear phagocyte system can dimin- ish tumor-targeting efficiency and increase off-target accumulation in organs such as the liver and spleen, raising safety concerns. Regulatory pathways for complex nano- formulations remain relatively uncertain, with demanding requirements for charac- terization, pharmacokinetic modeling, immunogenicity testing, and long-term safety monitoring that few phytochemical-based nanomedicines have yet met (Đorđević et al. 2022; Parvin et al. 2025). Furthermore, patient-to-patient differences in tumor vas- culature, enhanced permeability and retention (EPR) effect, and immune status may Sharaf et al. Cancer Nanotechnology (2026) 17:24 Page 21 of 26 limit the generalizability of preclinical results and necessitate personalized or stratified approaches to NP design (Đorđević et al. 2022; Parvin et al. 2025). Addressing these challenges (also illustrated in Fig. 3) will require integrated efforts in materials science, pharmacology, toxicology, and regulatory science to develop robust, scalable, and clini- cally translatable nanoformulations.

    Sustainable nanomedicine: exploiting fruit and vegetable waste-derived extracts for targeted anticancer application · 2026 · DOI

  • to associated with antioxidant their bioavailability and solubility (Sezgin-Bayindir et al., 2023). This review explores antioxidants roles in breast cancer focusing on plant-based antioxidants and discusses how different drug delivery systems enhance antioxidant-based breast cancer treatment.

    Recent advances in the delivery of natural-product antioxidants for the treatment of breast cancer · 2026 · DOI

  • Although the study demonstrates that combination therapy more effectively optimizes the Th17/Treg balance and shows stronger correlations with disease activity index, the minimal advantage in hemoglobin and red blood cell improvement between groups warrants investigation into whether prolonged combination therapy (beyond 26 weeks) with curcumin's mucosal repair properties produces cumulative benefits in inflammation-associated anemia correction.

    Effect of curcumin combined with vedolizumab on disease activity in patients with moderate to severe ulcerative colitis and its correlation with inflammatory and immune factors · 2026 · DOI

  • The study compared moderate versus severe ulcerative colitis subgroups but did not stratify analysis by baseline inflammatory phenotype (Th17-dominant versus Treg-deficient) or specific genetic polymorphisms in IL-10, IL-6, or integrin genes that might predict differential responses to the curcumin-vedolizumab combination therapy.

    Effect of curcumin combined with vedolizumab on disease activity in patients with moderate to severe ulcerative colitis and its correlation with inflammatory and immune factors · 2026 · DOI

  • The pronounced decline in fecal calprotectin in the combination group is attributed to both vedolizumab's suppression of neutrophil recruitment and curcumin's antioxidant and epithelial barrier repair properties, but direct quantification of intestinal epithelial barrier function recovery (through transepithelial electrical resistance or zonula occludens-1 expression) was not measured to validate this proposed mechanism.

    Effect of curcumin combined with vedolizumab on disease activity in patients with moderate to severe ulcerative colitis and its correlation with inflammatory and immune factors · 2026 · DOI

  • While the study demonstrated stronger positive correlations between disease activity index and both Th17/Treg ratio and CRP in the combination group, the mechanistic basis for why curcumin's NF-κB pathway inhibition synergizes specifically with vedolizumab's α4β7 integrin blockade has not been directly tested through pathway-level investigation or in vitro co-culture models of intestinal T cells.

    Effect of curcumin combined with vedolizumab on disease activity in patients with moderate to severe ulcerative colitis and its correlation with inflammatory and immune factors · 2026 · DOI

  • The study observed that IL-10 levels were significantly higher in the curcumin-vedolizumab combination group compared to vedolizumab alone only at week 14, but this difference was not maintained at week 26. The temporal kinetics and mechanisms underlying this differential IL-10 expression pattern require investigation with more frequent sampling time points to elucidate the dynamic IL-10 profile during early versus late phases of inflammation resolution under combination therapy.

    Effect of curcumin combined with vedolizumab on disease activity in patients with moderate to severe ulcerative colitis and its correlation with inflammatory and immune factors · 2026 · DOI

  • While the paper notes that flavonoids and phenols inhibit S. aureus growth through enzyme disruption, the specific molecular mechanisms of how turmeric compounds modulate IL-1, IL-6, and IL-8 levels require further elucidation.

    Enhancing immunity: antioxidant and immunomodulatory properties of steam blanching-prepared turmeric (Curcuma domestica Val.) powder · 2026 · DOI

  • Sepsis is a severe, life-threatening condition resulting from an overwhelming host response to an infection. It continues to pose a challenge in critical care due to its high morbidity and mortality rates. Sepsis is associated with systemic inflamma- tion, immune dysregulation, and diffuse organ malfunction and requires immediate and appropriate therapeutic inter- ventions. Curcumin has been considered as a supplement in the management of sepsis owing to its anti‑inflammatory, antioxidant and immune-modulating effects. As aforemen- tioned, preclinical and early clinical studies have shown that curcumin influences the key pathways of the sepsis cascade by inhibiting proinflammatory cytokines, reducing oxidative stress, and modulating immune responses. Given its multifaceted effects, curcumin may reduce the severity of sepsis, improve outcomes, and reduce serious complications such as organ failure. These results, although encouraging, warrant further studies in terms of their activity and safety profiles to define their optimal role in the management of sepsis, especially in larger clinical trials. In-depth studies are therefore warranted to fully elucidate the therapeutic poten- tial of curcumin in the management of sepsis. Optimization of the bioavailability and delivery methods for curcumin should be the primary focus, as poor absorption and rapid metabolism limit its clinical applications. Improvements in nanoparticle-based delivery systems or formulation advance- ments may enhance the potency of curcumin. Clinical trials of curcumin may be necessary to define its optimal dosage and duration of therapy and to identify possible interactions with standard sepsis therapies. Furthermore, the synergistic effect of curcumin can be increased when used concurrently with other therapeutic agents, thereby providing a more effective and multidimensional treatment approach. The therapeutic incorporation of curcumin in sepsis management will depend on a deeper understanding of its pharmacoki- netics and mechanisms of action, ultimately enabling clinical translation and fostering innovative strategies for more effective treatment.

    From spice to sepsis therapy: Mechanistic perspectives on the anti-sepsis therapeutic potential of curcumin (Review) · 2026 · DOI

  • Introduction Sepsis. Sepsis is a severe condition characterized by a dysregulated host inflammatory response to infection, resulting in organ damage. The latest Global Burden of Disease 2021 analysis estimated 166 million cases of sepsis worldwide in 2021 and ~21.4 million sepsis-related deaths, collectively accounting for almost 31.5% of the total global mortality (1). A constant decline in sepsis-related mortality between 1990 and 2019 was followed by a sharp trend reversal in 2020 and 2021 globally, which was significantly attributed to the coronavirus disease 2019 (COVID-19) pandemic and increased susceptibility in elderly populations. The incidence of sepsis increased by 230% and mortality increased by 26.3% since 1990 among adults aged ≥15 years, with the highest mortality rates being reported among the oldest age group (≥70 years; 9.28 million deaths in 2021). Although the incidence of sepsis-related deaths from infectious conditions, such as diarrheal diseases, tuberculosis, measles and lower respiratory infections has considerably decreased over the past three decades, fatalities related to non-infectious underlying conditions such as stroke, chronic obstructive pulmonary disease, cirrhosis, and ischemic heart disease have increased, highlighting the shift in sepsis epidemiology toward complications of chronic diseases (1). A previous study found that children aged <5 years constituted 26.4% (2.9 million) of the global sepsis death toll and 41.5% (20.3 million) of the cases of sepsis. The incidence of sepsis was lower among children and the younger population aged 5-19 years, accounting for 10% (4.9 million) and 4.1% (0.45 million associated deaths), respectively. Adults aged ≥20 years accounted for the majority of incident cases of sepsis, 2 AGARWAL et al: THERAPEUTIC POTENTIAL OF CURCUMIN IN SEPSIS representing 48.5% (23.7 million), and for 70% (7.7 million) of associated deaths. Men had a higher sepsis-related mortality rate than women (164 vs. 134 per 100,000, respectively), whereas women had a higher incidence of sepsis globally at 717 vs. 643 cases per 100,000 (2). Moreover, significant geographical and economic disparities have been reported, with high rates in low- and middle-income countries or countries with an intermediate sociodemographic index, such as those located in sub-Saharan Africa and South-East Asia (3). The frequency of sepsis greatly varies by location. The aforementioned scenario supports the view that the incidence of sepsis has decreased in children and is no longer mainly driven by infections; however, the overall global burden of sepsis is high and mostly driven by aging populations, chronic diseases, and new infections such as COVID-19 (1). It poses a major challenge globally, owing to its increasing incidence and high mortality rates, and also poses a tremendous financial burden on healthcare systems.

    From spice to sepsis therapy: Mechanistic perspectives on the anti-sepsis therapeutic potential of curcumin (Review) · 2026 · DOI

  • Combination-drug therapy allows synergistic therapy by simultaneously stimulating multiple pathways or enhancing the pharmacokinetic performance of one or more drugs. There are many mechanisms for synergistic therapy; however, not all therapeutic agents effectively work when combined.460 Chemical interference between therapeutic agents may reduce their combined action compared to the estimated sum of effort. Antagonism may occur if two compounds act competitively on the same target, reducing their combined activity. Therefore, verifying the relationship between their is necessary to ensure synergistic therapy when designing a combination therapy using two or more drugs. Computer-aided design can quickly and efficiently screen suitable drug combinations with synergistic effects. Moreover, the clinicians reported some potential drug combinations through clinical practices, and the combined treatment model has been utilized to treat various diseases (Tables 1–3). therapeutic index and synergy coefficient Administering multiple drugs directly (mostly intravenously) always leads to compromised treatment efficacy because the drugs must cross many biological barriers before and after entering systemic circulation.461–463 Therefore, developing codelivery systems is vital for therapy as designing combination strategies.464,465 Over the years, NP-codelivery systems have been exploited with other therapeutic agents to treat various diseases.

    Multifunctional nanoparticle-mediated combining therapy for human diseases · 2024 · DOI

  • Future studies should focus on developing optimized curcumin formulations with improved pharmacokinetics, exploring combinatorial regimens with ceramide analogs or targeted inhibitors, and conducting well-designed clini- cal trials to validate preclinical observations.

    Curcumin as a ceramide metabolism-targeting agent: Molecular mechanisms and therapeutic implications in cancer · 2026 · DOI

  • The practical application of steam blanching-prepared turmeric powder as a functional food or therapeutic agent in clinical settings has not been demonstrated.

    Enhancing immunity: antioxidant and immunomodulatory properties of steam blanching-prepared turmeric (Curcuma domestica Val.) powder · 2026 · DOI

  • The study focused on specific rhizome variations and steam blanching duration; investigation of other turmeric varieties and alternative processing parameters remains unexplored.

    Enhancing immunity: antioxidant and immunomodulatory properties of steam blanching-prepared turmeric (Curcuma domestica Val.) powder · 2026 · DOI

Most-cited papers in Curcumin's Biomedical Applications

Most recent work

Find a gap in your own Curcumin's Biomedical Applications sub-topic

This page shows what the Curcumin's Biomedical Applications literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Biochemistry, Genetics and Molecular Biology

Gut microbiota and health
289 open questions
Single-cell and spatial transcriptomics
185 open questions
dental development and anomalies
121 open questions
Mitochondrial Function and Pathology
110 open questions
Genetic Associations and Epidemiology
106 open questions
Human-Animal Interaction Studies
105 open questions
Genomics and Chromatin Dynamics
97 open questions
Inflammatory Bowel Disease
91 open questions
25 open questions have been extracted from the limitations and future-work passages of 218 Curcumin's Biomedical Applications papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.